A phase I and pharmacokinetic study of BAY59: A novel taxane

Oncology

Volumn 67, Issue 2, 2004, Pages 123-129

  Ramnath, N ^a   Hamm, J ^b   Schwartz, G ^a   Holden, S ^c   Eckhardt, S G ^c   Vredenburg, M R ^a   Bernacki, R J ^a   Lathia, C ^d   Kanter, P ^a   Creaven, P J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Norton Healthcare   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d BAYER CORPORATION   (United States)

Author keywords

Drug resistance; P Glycoprotein

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BAY 59; DEXAMETHASONE; DIPHENHYDRAMINE; OXALIPLATIN; RANITIDINE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; FATIGUE; FEMALE; FEVER; HUMAN; HYPONATREMIA; KIDNEY FUNCTION; LEG PAIN; LIVER FUNCTION; MALAISE; MALE; MAXIMUM TOLERATED DOSE; MUSCLE WEAKNESS; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 8344247107     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080998     Document Type: Article

References (8)

1. Horwitz SB, Lothstein L, Manfredi JJ, Mellado W, Parness J, Roy SN, Schiff PB, Sorbara L, Zehab R: Taxol mechanisms of action and resistance. Ann N Y Acad Sci 1986;466:733-744.
2. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-7738.
3. Vredenburg MR, Ojima I, Veith J, Pera P, Kee K, Cabral F, Sharma S, Kanter P, Greco WR, Bernacki RJ: Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance. J Natl Cancer Inst 2001;93:1234-1245.
4. Faries D: Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat 1994;4:147-164.
5. Loos WJ, Szebeni J, ten Tije AJ, Verweij J, van Zomeren DM, Chung KN, Nooter K, Stoter G, Sparreboom A: Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel. Anticancer Drugs 2002;13:767-775.
6. Laccabue D, Tortoreto M, Veneroni S, Perego P, Scanziani E, Zucchetti M, Zaffaroni M, D'Incalci M, Bombardelli E, Zunino F, Pratesi G: A novel taxane active against an orthotopically growing human glioma xenograft. Cancer 2001;92:3085-3092.
7. Laurence V, Pierga JY, Beuzeboc P, Piperno-Neumann S, Landon F, Grange V, Barouki F, Brendel E, Schwartz V, Dieras V: A phase I and pharmacokinetic study of a novel taxane BAY 59-88862 with a weekly schedule. Proc ASCO 2003;22:161.
8. Tonkin K, Herbert H, Lathia C, Gallentine M, Hobdy E, Schwartz B: A phase I and pharmacokinetic study of a novel oral taxane BAY 59-8862 in solid tumors. Proc ASCO 2003;22:241.